CurrentUnitedHealthcarePolicy CS374KY.02

Electrical stimulation for wound healing (Kentucky)

UnitedHealthcare Kentucky medical policy CS374KY.02 addresses coverage for electrical stimulation (ES) therapy for wound healing, specifying indications, required conventional care prior to ES, exclusions for other wound types, applicable procedure codes, and supporting evidence.

Policy Summary

PayerUnitedHealthcare

PolicyElectrical stimulation for wound healing (Kentucky)

Policy CodePolicy CS374KY.02

Change TypeSupporting Information Updated

Effective DateApr 1, 2025

Next Review Date

Key ActionDocument that the pressure ulcer is Stage III or IV and that it failed to demonstrate Measurable Signs of Healing after 30 days of conventional care, including specified elements (turning/positioning, dressings, debridement if present, infection management if present, nutrition evaluation, moisture/incontinence management, pressure-reducing support surface).

SourceLink

POLICY UPDATE CHANGES

Supporting Information Updated Clinical Evidence and References sections to reflect the most current information; archived previous policy version CS374KY.01.

1State-specific policy (Kentucky only)

2HCPCS codes referenced

2Covered pressure ulcer stages

References updatedPolicy Revision Note

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

UnitedHealthcare Kentucky Medical Policy CS374KY.02 (Effective April 1, 2025) provides a mixed coverage stance for electrical stimulation (ES) for wound healing. ES is medically necessary/covered for Stage III or Stage IV pressure ulcers that have not shown Measurable Signs of Healing after a 30-day trial of conventional care (see required conventional care elements). ES is unproven and not medically necessary for diabetic ulcers, venous stasis ulcers, and other wounds that do not meet the Stage III/IV failed 30-day conventional care criteria. Applicable HCPCS codes referenced include G0281 and G0282.

Conventional care trial duration30 days

Covered pressure ulcer stagesStage III and Stage IV

HCPCS codes referencedG0281, G0282

Medical Necessity Criteria

Coding

Referenced procedure codesHCPCS

G0281	Electrical stimulation, (unattended); to one or more areas, for chronic Stage III and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers, and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care, as of a therapy plan of care part.
G0282	Electrical stimulation, (unattended), to one or more areas, for wound care other than described in G0281

Provider Actions

Prior Authorization

Prior authorization / medical necessity verification

Prior authorization/medical necessity verification: provider must document the pressure ulcer is Stage III or IV and that the ulcer failed to demonstrate Measurable Signs of Healing after a 30‑day trial of conventional care. The 30‑day conventional care trial must include the specified elements listed below and be clearly recorded in the medical record.

Affected HCPCS codes: G0281, G0282
Conventional care elements required: appropriate turning and positioning; application of dressings to maintain a moist wound environment; debridement of necrotic tissue, if present; management of existing infection, if present; evaluation of and provision for adequate nutritional status; moisture and incontinence management; use of a pressure‑reducing support surface

Documentation Required

Document measurable signs of healing and conventional care

Clinical records must document measurable signs of healing and the conventional care provided during the 30‑day trial. Wound assessments should include objective measurements and descriptions so the claim can be reviewed against the policy criteria.

Background & Evidence

Electrical stimulation therapy applies low-level electrical currents to a wound using at least two electrodes connected to a small battery-like device; the device delivers short bursts of current that alter the charge across the wound bed, modify cell membrane potential, and promote angiogenesis to accelerate healing.

The FDA has not approved devices specifically for chronic wound treatment; these devices are regulated as Class II medical devices, and many have been cleared through the 510(k) process.

Source	Summary
Cochrane review (Arora et al. 2020)	ES probably increases proportion of pressure ulcers healed (RR 1.99; 95% CI 1.39 to 2.85; 11 studies, 501 participants); certainty of evidence ranges moderate to very low; effect on time to complete healing uncertain.
Systematic reviews / meta-analyses (Chen 2022; Girgis & Duarte 2018; Khouri 2017; Lala 2016; others)	Multiple reviews/meta-analyses show benefit of ES for pressure ulcers (reduced wound surface area, increased healing rates); HVMPC and pulsed current often reported as more effective; overall study heterogeneity and variable quality limit conclusions; evidence for diabetic and venous ulcers is mixed or insufficient.
Recent trials / reviews cited (e.g., Avendano-Coy 2022; Polak 2018; Avazzadeh 2020; Zulbaran-Rojas 2023)	Recent RCTs and trials report improved wound area reduction, PUSH score improvements, and some complete healings with ES modalities (microcurrent, HVMPC); small sample sizes, variable parameters, and mixed results for non-pressure ulcers noted.
Systematic reviews on diabetic foot ulcers (Chen 2020; Zheng 2022; Melotto 2022; Girgis 2023)	Meta-analyses report ES may reduce ulcer area and increase healing rates for DFUs in some trials, but high heterogeneity, small studies, and risk of bias lead to insufficient evidence to recommend routine use; pulsed current may be more beneficial.
Systematic reviews on venous leg ulcers (Borges et al. 2023; Ashrafi 2017)	Some RCTs and case series show VLU outcome improvements with EST, particularly monophasic pulsed currents; overall evidence quality is poor and protocols vary, requiring further research.
Effect size and modality-focused analyses (Khouri 2017; Girgis 2018)	Effect size meta-analyses indicate a moderate-to-large overall effect of ES on chronic wound healing, with HVPC/HVMPC and pulsed currents showing stronger effects, particularly for pressure ulcers; efficacy may vary by wound etiology, size, and duration.
Guidelines and professional recommendations (ACP 2015; NPUAP/EPUAP/PPPIA 2019; IWGDF 2016; NICE 2015; Society for Vascular Surgery 2014)	ACP gives a weak recommendation (moderate-quality evidence) for ES as adjunctive therapy for pressure ulcers; NPUAP guideline supports pulsed current ES for recalcitrant/stage II–IV pressure injuries; IWGDF and NICE recommend against routine ES for diabetic foot ulcers outside trials; Society for Vascular Surgery does not recommend ES for venous leg ulcers due to limited and inconsistent evidence.

Definitions

Measurable Signs of Healing: Wound is diminishing in size (surface or depth) with decreased amount of exudate and necrotic tissue.

Stage III pressure ulcer: Full-thickness loss of skin with visible fat; slough or eschar may be present; fascia, muscle, tendon, ligament, cartilage, and/or bone are not exposed.

Stage IV pressure ulcer: Full-thickness skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage, or bone.

Revision History

2025-04-01policy_revisionLatest

Supporting Information Updated Clinical Evidence and References sections to reflect the most current information; archived previous policy version CS374KY.01. Change marked as non-material.

2025-04-01archival

Archived previous policy version CS374KY.01.